spacer
The Healthcare Sales & Marketing Network celebrates 28 years serving the medical sales & marketing community.Connecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product LinesConnecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product Lines

Searching News Database:  myeloperoxidase 

 HSMN NewsFeed - 4 Jan 2021
Biohaven Begins Pivotal Phase 3 Trial Of Troriluzole In Obsessive-Compulsive Disorder
Biopharmaceuticals
 HSMN NewsFeed - 10 Jun 2020
Biohaven Appoints Bob Hugin to its Board of Directors
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 23 Mar 2020
Biohaven to Advance Vazegepant into Phase 3 for the Acute Treatment of Migraine Following Successful End of Phase 2 Meeting with FDA
Biopharmaceuticals FDA
 HSMN NewsFeed - 18 Mar 2020
Biohaven's Verdiperstat Receives Fast Track Designation For The Treatment Of Multiple System Atrophy
Biopharmaceuticals FDA
 HSMN NewsFeed - 10 Feb 2020
Biohaven's Troriluzole Study For Generalized Anxiety Disorder (GAD) Misses Primary Endpoint
Biopharmaceuticals
 HSMN NewsFeed - 18 Sep 2019
Biohaven's Verdiperstat, An Oral Myeloperoxidase Inhibitor, Selected For Platform Trial Collaboration At Massachusetts General Hospital's Healey & AMG Center For Amyotrophic Lateral Sclerosis (ALS)
Biopharmaceuticals Neurology
 HSMN NewsFeed - 31 Jul 2019
Biohaven Enrolls First Patient In Phase 3 Clinical Trial Of Verdiperstat, Oral Myeloperoxidase Inhibitor, For The Treatment Of Multiple System Atrophy
Biopharmaceuticals Neurology
 HSMN NewsFeed - 10 Dec 2018
Biohaven Announces Positive Results from Ongoing Rimegepant Long-Term Safety Study
Biopharmaceuticals Neurology
 HSMN NewsFeed - 26 Nov 2018
Biohaven Announces FDA Acceptance of 505(b)(2) NDA Filing for BHV-0223, a Novel Sublingual Delivery Form of Riluzole for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
Biopharmaceuticals Neurology Drug Delivery FDA
 HSMN NewsFeed - 12 Sep 2018
Biohaven Appoints Bob Repella to Board of Directors
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 6 Mar 2014
Boston Heart Enables Healthcare Providers to Better Identify Near-Term Risk of Heart Attack or Stroke with Launch of an Important Inflammation Marker, Myeloperoxidase (MPO)
Diagnostics Cardiology Product Launch
 HSMN NewsFeed - 4 Nov 2008
Inverness Medical Innovations, PrognostiX Sign Distribution Agreement for CardioMPO(TM) Test
Diagnostics Cardiology Distribution
 HSMN NewsFeed - 20 Dec 2007
Hollis-Eden Pharmaceuticals Announces Cystic Fibrosis Foundation Therapeutics Selects TRIOLEX(TM) (HE3286) as a Next-Generation Oral Anti-Inflammatory Drug Candidate
Biopharmaceuticals
 HSMN NewsFeed - 27 Jun 2007
Beckman Coulter Grants Sublicense to Dade Behring for Novel Cardiac Markers
Diagnostics Licensing
 HSMN NewsFeed - 9 Apr 2007
OXIS International Expands Licensing Deal with Alteon to Include Exclusive Rights of Organoselenium Compounds for All Indications
Biopharmaceuticals Licensing
Return to NewsFeed  

 Additional items found! 6

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 6 additional stories matching:
myeloperoxidase
(Password required)
FindReps - screen and connect with rep candidates anonymously, in real time.

FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.


RepJobs - Job Opportunities for Direct Sales Reps and New Product Lines for Independents!

RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!